- Home
- NXC vs ONCY Comparison
NXC vs ONCY Comparison
Compare NXC & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXC
- ONCY
- Stock Information
- Founded
- NXC 1992
- ONCY 1998
- Country
- NXC United States
- ONCY Canada
- Employees
- NXC N/A
- ONCY N/A
- Industry
- NXC Investment Managers
- ONCY Pharmaceuticals and Biotechnology
- Sector
- NXC Finance
- ONCY Health Care
- Exchange
- NXC Nasdaq
- ONCY Nasdaq
- Market Cap
- NXC 87.3M
- ONCY 86.1M
- IPO Year
- NXC N/A
- ONCY 1999
- Fundamental
- Price
- NXC $13.13
- ONCY $0.83
- Analyst Decision
- NXC
- ONCY Strong Buy
- Analyst Count
- NXC 0
- ONCY 2
- Target Price
- NXC N/A
- ONCY $4.00
- AVG Volume (30 Days)
- NXC 17.5K
- ONCY 437.8K
- Earning Date
- NXC 01-01-0001
- ONCY 11-12-2024
- Dividend Yield
- NXC 3.97%
- ONCY N/A
- EPS Growth
- NXC N/A
- ONCY N/A
- EPS
- NXC 0.19
- ONCY N/A
- Revenue
- NXC N/A
- ONCY N/A
- Revenue This Year
- NXC N/A
- ONCY N/A
- Revenue Next Year
- NXC N/A
- ONCY N/A
- P/E Ratio
- NXC $70.47
- ONCY N/A
- Revenue Growth
- NXC N/A
- ONCY N/A
- 52 Week Low
- NXC $11.86
- ONCY $0.71
- 52 Week High
- NXC $13.70
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- NXC 39.78
- ONCY 42.01
- Support Level
- NXC $13.15
- ONCY $0.71
- Resistance Level
- NXC $13.29
- ONCY $0.93
- Average True Range (ATR)
- NXC 0.16
- ONCY 0.06
- MACD
- NXC -0.01
- ONCY 0.00
- Stochastic Oscillator
- NXC 23.44
- ONCY 55.00
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing primarily in municipal obligations.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.